Septerna (SEPN) Insider Alan Ezekowitz Buys 15,000 Shares

Alan Ezekowitz Buys Shares of Septerna, Inc.

Alan Ezekowitz recently picked up 15,000 shares of Septerna, Inc. SEPN on June 26, 2026. This transaction adds to insider engagement at the clinical-stage biotechnology firm, reflecting participation from key figures around the same date.

More Insiders Step In Alongside Alan Ezekowitz

The June 26, 2026 trade by Alan Ezekowitz formed part of a wider group of insider purchases at the company. Shalini Sharp also acquired 15,000 shares on June 26, 2026. At the same time, L.P. Ra Capital Management added 15,000 shares on June 26, 2026, and Bernard Coulie purchased 15,000 shares on June 26, 2026. These coordinated transactions highlight shared insider interest as the company moves forward with its drug development pipeline.

Septerna Stock Trades Across Its Range

Septerna shares trade around $33.49, sitting comfortably between a 52-week low of $15.86 and a 52-week high of $51.10. The company carries a market capitalization of $1.80 billion. The stock's 50-day moving average sits at $38.14, while its 200-day moving average rests at $30.31.

Recent Earnings and Financial Health

For its recent financial period, Septerna reported $98.88 million in revenue alongside a revenue growth rate of 223.76%. The firm recorded an earnings per share figure of -$0.53, paired with a net margin of -24.51% and a return on equity of -6.34%. The balance sheet shows a current ratio of 5.00 and a quick ratio of 4.90, alongside a debt-to-equity ratio of 5.83. The company's next corporate earnings release is scheduled for November 9, 2026.

Wall Street Analysts Update Coverage

Wall Street firms have remained active in reviewing the stock alongside these corporate developments. On August 19, 2026, JP Morgan maintained an overweight rating on the stock with a $48.00 price target. Jones Trading kept a buy rating on August 13, 2026, lifting its target to $62.00. Wells Fargo held an overweight rating on August 12, 2026, with a $50.00 target, while HC Wainwright & Co. maintained a buy rating with a $60.00 target. Guggenheim also held a buy rating with a $51.00 target on August 11, 2026. Overall, the stock carries a strong buy recommendation from analysts, backed by a mean price target of $54.22 across nine analyst opinions.

Inside the Biotechnology Pipeline

Septerna, Inc. discovers and develops G protein-coupled receptor oral small molecule products focused on endocrinology, immunology, inflammation, and metabolic diseases. Its pipeline includes programs targeting hypoparathyroidism, chronic spontaneous urticaria, and thyroid eye disease, alongside a global collaboration with Novo Nordisk for metabolic-related therapies. Headquartered in South San Francisco, California, the firm employs 123 people.

What to Watch Next for Septerna

Investors will look toward the upcoming earnings report on November 9, 2026, for fresh updates on the clinical pipeline and financial execution. Future regulatory filings will also show whether insiders continue adjusting their holdings as these research programs progress.